temozolomide and Thrombopenia studies

Research Excerpts

Excerpt	Relevance	Reference
"In this article, we have compared and analyzed the clinical effects of temozolomide single agent and combined doxorubicin in the treatment of glioma."	9.51	Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma. ( Chen, L; Liu, Y, 2022)
"To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma."	9.30	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. ( Cartalat, S; Chinot, O; Devos, P; Di Stefano, AL; Dubois, F; Houillier, C; Le Rhun, E; Lepage, C; Reyns, N; Weller, M, 2019)
"A total of 17 consecutive patients in four cohorts with World Health Organization Grade 3 (n = 2) and 4 (n = 15) gliomas were given tamoxifen twice daily during 6 weeks of concurrent RT and temozolomide."	9.16	Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. ( Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S, 2012)
"To determine the response rate (RR) of neuroblastoma (NB) in children to temozolomide (TMZ), and evaluate the duration of response and tolerance of the drug in this patient population."	9.12	Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. ( Auvrignon, A; Baunin, C; Bergeron, C; Biassoni, L; Brisse, H; Chisholm, J; Coze, C; Defachelles, AS; Dickinson, F; Djafari, L; Giammarile, F; Hobson, R; McHugh, K; Morland, B; Mosseri, V; Munzer, C; Rubie, H; Valteau-Couanet, D; Vassal, G; Weston, C, 2006)
"Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain."	9.12	A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007)
"The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma."	9.12	Phase II trial of temozolomide in children with recurrent high-grade glioma. ( Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2006)
"Cisplatin and temozolomide (TMZ) are active in glioblastoma multiforme (GBM), with different profiles of toxicity."	9.11	First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. ( Basso, U; Brandes, AA; Cavallo, G; Ermani, M; Ferreri, AJ; Monfardini, S; Panucci, MG; Reni, M; Scopece, L; Tosoni, A; Vastola, F, 2004)
"Temozolomide, a DNA methylating agent used to treat melanoma, induces DNA damage, which is repaired by O6-alkylguanine alkyltransferase (ATase) and poly(ADP-ribose) polymerase-1 (PARP-1)-dependent base excision repair."	9.11	Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. ( Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005)
"Temozolomide is an oral alkylating agent that readily crosses the blood-brain barrier and has activity in patients with advanced melanoma."	9.10	A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. ( Boxall, J; Marples, M; Meyer, T; Napier, MP; Rustin, GJ; Strauss, SJ, 2003)
"Temozolomide is a novel oral alkylating agent that is effective against melanoma."	9.10	Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. ( Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D, 2002)
"Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma."	9.10	Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003)
"Despite moderate toxicity, objective response rates to temozolomide have been low, indicating that temozolomide has minimal activity in the high-grade gliomas of childhood."	9.10	Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. ( Couanet, D; Doz, F; Dugan, M; Frappaz, D; Griffiths, PD; Hobson, R; Ironside, J; Jaspan, T; Jouvet, A; Lashford, LS; Pearson, AD; Robson, K; Thiesse, P; Vassal, G, 2002)
"Temozolomide in the schedule used has as good activity in chemotherapy-naive metastatic melanoma as the other most active agents currently in use."	9.08	Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. ( Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N, 1995)
"We retrospectively analyzed cytopenia during temozolomide-based concomitant radiochemotherapy in 492 patients with glioma."	8.12	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. ( Filipski, K; Filmann, N; Fokas, E; Forster, MT; Harter, PN; Herrlinger, U; Ronellenfitsch, MW; Steinbach, JP; Voss, M; Zeiner, PS, 2022)
"Chemo-induced thrombocytopenia is a limiting toxicity among patients receiving temozolomide (TMZ) as first-line treatment for glioblastoma."	7.96	Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma. ( Alexandru, C; Basuyau, F; Clatot, F; Di Fiore, F; Fontanilles, A; Fontanilles, M; Hanzen, C; Joannidès, R; Lamoureux, F; Langlois, O; Massy, N; Pereira, T; Rouvet, J; Tennevet, I, 2020)
"Temozolomide (TMZ) is known to induce thrombocytopenia but no early predictive test has yet been clearly established."	7.91	Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients. ( Alexandru, C; Clatot, F; David, M; Di Fiore, F; Fontanilles, M; Gilard, V; Hanzen, C; Langlois, O; Laquerriere, A; Marguet, F; Tennevet, I; Veresezan, O, 2019)
"An integrated protocol combining capecitibine-temozolomide with yttrium-90 radioembolization (CapTemY90) for liver-dominant grade 2 neuroendocrine tumors (NETs) was designed in the hope of achieving synergistic improvement in liver disease control with no more than additive toxicities."	7.88	Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors. ( Cengel, KA; Damjanov, N; Metz, DC; Soulen, MC; Teitelbaum, UR; van Houten, D, 2018)
"To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies."	7.79	A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013)
" We present the case of a 26-year-old male suffering a fatal ICH in the context of treatment of a high grade glioma with temozolomide."	7.76	Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. ( Anderson, WS; Dunn, I; Norden, A; Sure, D, 2010)
"We report a case of a 51-year-old woman with newly diagnosed glioblastoma multiforme (GBM) who was treated with surgery followed by the standard concomitant temozolomide (TMZ) and radiotherapy (RT)."	7.75	Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. ( Fujioka, Y; Homori, M; Kurita, H; Miyazaki, H; Nagane, M; Nozue, K; Shimizu, S; Shiokawa, Y; Waha, A, 2009)
"Glioblastoma is the most common and most aggressive type of primary brain tumor."	7.30	Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma. ( Bu, XY; Cheng, X; Kong, LF; Luo, JC; Qu, MQ; Wang, YW; Yan, ZY; Yang, DY; Zhao, YW, 2023)
" We aimed to determine whether or not pulse high-dose lapatinib was a safe and tolerable regimen in addition to standard therapy."	6.84	Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017)
"Seventy-one eligible patients 70 years of age or older with newly diagnosed GBM and a Karnofsky performance status ≥60 were treated with a short course of RT (40 Gy in 15 fractions over 3 weeks) plus TMZ at the dosage of 75 mg/m(2) per day followed by 12 cycles of adjuvant TMZ (150-200 mg/m(2) for 5 days during each 28-day cycle)."	6.77	Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. ( Arcella, A; Caporello, P; De Sanctis, V; Enrici, RM; Giangaspero, F; Lanzetta, G; Minniti, G; Salvati, M; Scaringi, C, 2012)
" Metronomic dosing of temozolomide (TMZ) combined with standard radiotherapy may improve survival by increasing the therapeutic index and anti-angiogenic effect of TMZ."	6.75	A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. ( Bartels, U; Baruchel, S; Bouffet, E; Eisenstat, D; Gammon, J; Huang, A; Hukin, J; Johnston, DL; Samson, Y; Sharp, JR; Stempak, D; Stephens, D; Tabori, U, 2010)
"Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies."	6.74	A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. ( Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ, 2009)
"The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor."	6.74	Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. ( Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH, 2009)
" Therefore, the authors initiated a Phase I study to determine the pharmacokinetics and safety profile of temozolomide (TMZ), a novel oral alkylating agent known to cross the blood-brain barrier, in combination with interferon alpha-2b (IFN-alpha2b)."	6.71	Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. ( Agarwala, SS; Kirkwood, JM, 2003)
"In this article, we have compared and analyzed the clinical effects of temozolomide single agent and combined doxorubicin in the treatment of glioma."	5.51	Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma. ( Chen, L; Liu, Y, 2022)
"There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)."	5.43	Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016)
"To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma."	5.30	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. ( Cartalat, S; Chinot, O; Devos, P; Di Stefano, AL; Dubois, F; Houillier, C; Le Rhun, E; Lepage, C; Reyns, N; Weller, M, 2019)
"Cabozantinib inhibits mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabozantinib to radiotherapy (RT) and temozolomide (TMZ) for patients with newly diagnosed high-grade glioma."	5.22	Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. ( Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY, 2016)
"A total of 17 consecutive patients in four cohorts with World Health Organization Grade 3 (n = 2) and 4 (n = 15) gliomas were given tamoxifen twice daily during 6 weeks of concurrent RT and temozolomide."	5.16	Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. ( Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S, 2012)
"To determine the response rate (RR) of neuroblastoma (NB) in children to temozolomide (TMZ), and evaluate the duration of response and tolerance of the drug in this patient population."	5.12	Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. ( Auvrignon, A; Baunin, C; Bergeron, C; Biassoni, L; Brisse, H; Chisholm, J; Coze, C; Defachelles, AS; Dickinson, F; Djafari, L; Giammarile, F; Hobson, R; McHugh, K; Morland, B; Mosseri, V; Munzer, C; Rubie, H; Valteau-Couanet, D; Vassal, G; Weston, C, 2006)
"The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma."	5.12	Phase II trial of temozolomide in children with recurrent high-grade glioma. ( Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2006)
"Temozolomide (TMZ) is an oral alkylating agent principally indicated for neurological malignancies including glioblastoma (GBM) and astrocytoma."	5.12	Temozolomide-induced aplastic anaemia: Case report and review of the literature. ( Gilbar, PJ; Mangos, HM; Pokharel, K, 2021)
"Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain."	5.12	A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007)
"Temozolomide, a DNA methylating agent used to treat melanoma, induces DNA damage, which is repaired by O6-alkylguanine alkyltransferase (ATase) and poly(ADP-ribose) polymerase-1 (PARP-1)-dependent base excision repair."	5.11	Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. ( Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005)
"Cisplatin and temozolomide (TMZ) are active in glioblastoma multiforme (GBM), with different profiles of toxicity."	5.11	First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. ( Basso, U; Brandes, AA; Cavallo, G; Ermani, M; Ferreri, AJ; Monfardini, S; Panucci, MG; Reni, M; Scopece, L; Tosoni, A; Vastola, F, 2004)
"Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma."	5.10	Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003)
"Temozolomide is an oral alkylating agent that readily crosses the blood-brain barrier and has activity in patients with advanced melanoma."	5.10	A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. ( Boxall, J; Marples, M; Meyer, T; Napier, MP; Rustin, GJ; Strauss, SJ, 2003)
"Temozolomide is a novel oral alkylating agent that is effective against melanoma."	5.10	Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. ( Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D, 2002)
"Despite moderate toxicity, objective response rates to temozolomide have been low, indicating that temozolomide has minimal activity in the high-grade gliomas of childhood."	5.10	Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. ( Couanet, D; Doz, F; Dugan, M; Frappaz, D; Griffiths, PD; Hobson, R; Ironside, J; Jaspan, T; Jouvet, A; Lashford, LS; Pearson, AD; Robson, K; Thiesse, P; Vassal, G, 2002)
"Temozolomide in the schedule used has as good activity in chemotherapy-naive metastatic melanoma as the other most active agents currently in use."	5.08	Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. ( Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N, 1995)
"We retrospectively analyzed cytopenia during temozolomide-based concomitant radiochemotherapy in 492 patients with glioma."	4.12	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. ( Filipski, K; Filmann, N; Fokas, E; Forster, MT; Harter, PN; Herrlinger, U; Ronellenfitsch, MW; Steinbach, JP; Voss, M; Zeiner, PS, 2022)
"Hematological adverse events (HAEs) are common during treatment for glioblastoma (GBM), usually associated with temozolomide (TMZ)."	4.12	Hematological adverse events in the management of glioblastoma. ( Butts, AR; Garcia, CR; Jayswal, R; Morgan, RM; Myint, ZW; Villano, JL; Wang, C; Weiss, HL, 2022)
"Chemo-induced thrombocytopenia is a limiting toxicity among patients receiving temozolomide (TMZ) as first-line treatment for glioblastoma."	3.96	Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma. ( Alexandru, C; Basuyau, F; Clatot, F; Di Fiore, F; Fontanilles, A; Fontanilles, M; Hanzen, C; Joannidès, R; Lamoureux, F; Langlois, O; Massy, N; Pereira, T; Rouvet, J; Tennevet, I, 2020)
"Temozolomide (TMZ) is known to induce thrombocytopenia but no early predictive test has yet been clearly established."	3.91	Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients. ( Alexandru, C; Clatot, F; David, M; Di Fiore, F; Fontanilles, M; Gilard, V; Hanzen, C; Langlois, O; Laquerriere, A; Marguet, F; Tennevet, I; Veresezan, O, 2019)
"An integrated protocol combining capecitibine-temozolomide with yttrium-90 radioembolization (CapTemY90) for liver-dominant grade 2 neuroendocrine tumors (NETs) was designed in the hope of achieving synergistic improvement in liver disease control with no more than additive toxicities."	3.88	Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors. ( Cengel, KA; Damjanov, N; Metz, DC; Soulen, MC; Teitelbaum, UR; van Houten, D, 2018)
"To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies."	3.79	A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013)
"Temozolomide (TMZ) is commonly used for the therapy of malignant glioma and induces thrombocytopenia in a fraction of patients."	3.77	Immature and absolute platelet count changes and thrombocytopenia in malignant glioma. ( Elandt, K; Heinzl, H; Marosi, C; Preusser, M; Schwarzinger, I, 2011)
" We present the case of a 26-year-old male suffering a fatal ICH in the context of treatment of a high grade glioma with temozolomide."	3.76	Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. ( Anderson, WS; Dunn, I; Norden, A; Sure, D, 2010)
"We report a case of a 51-year-old woman with newly diagnosed glioblastoma multiforme (GBM) who was treated with surgery followed by the standard concomitant temozolomide (TMZ) and radiotherapy (RT)."	3.75	Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. ( Fujioka, Y; Homori, M; Kurita, H; Miyazaki, H; Nagane, M; Nozue, K; Shimizu, S; Shiokawa, Y; Waha, A, 2009)
"Glioblastoma is the most common and most aggressive type of primary brain tumor."	3.30	Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma. ( Bu, XY; Cheng, X; Kong, LF; Luo, JC; Qu, MQ; Wang, YW; Yan, ZY; Yang, DY; Zhao, YW, 2023)
" We aimed to determine whether or not pulse high-dose lapatinib was a safe and tolerable regimen in addition to standard therapy."	2.84	Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017)
" There was no clear relationship between vorinostat dosage and drug exposure over the dose range studied."	2.78	A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. ( Ahern, C; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Horton, T; Hummel, TR; Ingle, AM; McGovern, RM; Reid, JM; Wagner, L; Weigel, B, 2013)
"Seventy-one eligible patients 70 years of age or older with newly diagnosed GBM and a Karnofsky performance status ≥60 were treated with a short course of RT (40 Gy in 15 fractions over 3 weeks) plus TMZ at the dosage of 75 mg/m(2) per day followed by 12 cycles of adjuvant TMZ (150-200 mg/m(2) for 5 days during each 28-day cycle)."	2.77	Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. ( Arcella, A; Caporello, P; De Sanctis, V; Enrici, RM; Giangaspero, F; Lanzetta, G; Minniti, G; Salvati, M; Scaringi, C, 2012)
" Metronomic dosing of temozolomide (TMZ) combined with standard radiotherapy may improve survival by increasing the therapeutic index and anti-angiogenic effect of TMZ."	2.75	A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. ( Bartels, U; Baruchel, S; Bouffet, E; Eisenstat, D; Gammon, J; Huang, A; Hukin, J; Johnston, DL; Samson, Y; Sharp, JR; Stempak, D; Stephens, D; Tabori, U, 2010)
"Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies."	2.74	A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. ( Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ, 2009)
"The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor."	2.74	Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. ( Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH, 2009)
"Temozolomide (TMZ) has shown modest efficacy in the treatment of recurrent brain metastasis (BM)."	2.72	Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. ( Abrey, LE; Demopoulos, A; Malkin, MG; Omuro, AM; Raizer, JJ, 2006)
" Therefore, the authors initiated a Phase I study to determine the pharmacokinetics and safety profile of temozolomide (TMZ), a novel oral alkylating agent known to cross the blood-brain barrier, in combination with interferon alpha-2b (IFN-alpha2b)."	2.71	Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. ( Agarwala, SS; Kirkwood, JM, 2003)
"To characterize and compare pharmacokinetic parameters in children and adults treated with temozolomide (TMZ) administered for 5 days in three doses daily, and to evaluate the possible relationship between AUC values and hematologic toxicity."	2.71	Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. ( Barone, C; Caldarelli, M; Cefalo, G; Garrè, ML; Lazzareschi, I; Madon, E; Maira, G; Massimino, M; Mastrangelo, S; Mazzarella, G; Riccardi, A; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2003)
" Alternate temozolomide dosing schedules such as continuous daily administration may enhance antitumor activity through sustained depletion of the DNA repair protein O6-alkylguanine DNA alkyltransferase."	2.71	Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. ( Baker, SD; Batra, VK; Cutler, DL; Donehower, RC; Rudek, MA; Statkevich, P, 2004)
"Temozolomide (TMZ) is a methylating agent of the imidotetrazine class, whose cytotoxic product is O(6)-methylguanine DNA adducts, which initiate a futile recycling of the mismatch repair pathway causing DNA strand breaks and apoptotic cell death in mismatch repair proficient cells."	2.70	Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. ( Gerson, SL; Haaga, J; Liu, L; Majka, S; Spiro, TP; Willson, JK, 2001)
" The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days."	2.70	Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. ( Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001)
"Temozolomide (TMZ) has demonstrated clinical antitumor activity."	2.45	The safety of temozolomide in the treatment of malignancies. ( Hwu, WJ; Patel, SP; Trinh, VA, 2009)
"There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)."	1.43	Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016)
"Thrombocytopenia was operationalized as a continuous platelet count and a dichotomic variable (cut-off <100."	1.38	Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. ( Blasco, J; Bruna, J; Gil, M; Graus, F; Pineda, E; Simó, M; Velasco, R; Verger, E, 2012)
" The aim of the present study was to evaluate the efficacy and side effects of nimotuzumab in combination with chemotherapy for patients with malignant gliomas."	1.37	[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. ( Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH, 2011)

Research

Studies (58)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Safest Dose of Temozolomide for the DRBEAT Regimen

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.72)	18.2507
2000's	24 (41.38)	29.6817
2010's	26 (44.83)	24.3611
2020's	7 (12.07)	2.80

Authors	Studies
Garcia, CR	1
Myint, ZW	1
Jayswal, R	1
Wang, C	1
Morgan, RM	1
Butts, AR	1
Weiss, HL	1
Villano, JL	1
Liu, Y	1
Chen, L	1
Zeiner, PS	1
Filipski, K	1
Filmann, N	1
Forster, MT	1
Voss, M	1
Fokas, E	1
Herrlinger, U	1
Harter, PN	1
Steinbach, JP	1
Ronellenfitsch, MW	1
Garzio, K	1
McElroy, K	1
Grossman, S	1
Holdhoff, M	1
Ozer, B	1
Yankulina, O	1
Yang, DY	1
Cheng, X	1
Bu, XY	1
Yan, ZY	1
Qu, MQ	1
Zhao, YW	1
Kong, LF	1
Wang, YW	1
Luo, JC	1
Le Rhun, E	1
Devos, P	1
Houillier, C	1
Cartalat, S	1
Chinot, O	1
Di Stefano, AL	1
Lepage, C	1
Reyns, N	1
Dubois, F	1
Weller, M	1
Fontanilles, M	2
Fontanilles, A	1
Massy, N	1
Rouvet, J	1
Pereira, T	1
Alexandru, C	2
Hanzen, C	2
Basuyau, F	1
Langlois, O	2
Clatot, F	2
Tennevet, I	2
Di Fiore, F	2
Joannidès, R	1
Lamoureux, F	1
Gilbar, PJ	1
Pokharel, K	1
Mangos, HM	1
Calegari, MA	1
Inno, A	1
Monterisi, S	1
Orlandi, A	1
Santini, D	1
Basso, M	1
Cassano, A	1
Martini, M	1
Cenci, T	1
de Pascalis, I	1
Camarda, F	1
Barbaro, B	1
Larocca, LM	1
Gori, S	1
Tonini, G	1
Barone, C	2
Yu, A	1
Faiq, N	1
Green, S	1
Lai, A	1
Green, R	1
Hu, J	1
Cloughesy, TF	1
Mellinghoff, I	1
Nghiemphu, PL	1
Arulananda, S	1
Lynam, J	1
Sem Liew, M	1
Wada, M	1
Cher, L	1
Gan, HK	1
Marguet, F	1
Veresezan, O	1
Gilard, V	1
David, M	1
Laquerriere, A	1
Marinelli, A	1
Lamberti, G	1
Cerbone, L	1
Cordua, N	1
Buonerba, C	1
Peluso, G	1
Di Lorenzo, G	1
De Placido, S	1
Soulen, MC	1
van Houten, D	1
Teitelbaum, UR	1
Damjanov, N	1
Cengel, KA	1
Metz, DC	1
Hummel, TR	1
Wagner, L	1
Ahern, C	1
Fouladi, M	1
Reid, JM	1
McGovern, RM	1
Ames, MM	1
Gilbertson, RJ	1
Horton, T	1
Ingle, AM	1
Weigel, B	1
Blaney, SM	1
Gupta, T	1
Mohanty, S	1
Moiyadi, A	1
Jalali, R	1
Saif, MW	1
Kaley, K	1
Brennan, M	1
Garcon, MC	1
Rodriguez, G	1
Rodriguez, T	1
Wang, XX	1
Huang, HQ	1
Bai, B	1
Cai, QQ	1
Cai, QC	1
Gao, Y	1
Xia, YF	1
Xia, ZJ	1
Jiang, WQ	1
Kesavan, M	1
Claringbold, PG	1
Turner, JH	1
Li, HL	1
Cui, XL	1
Zhang, JN	1
Lin, S	1
Schiff, D	2
Desjardins, A	2
Cloughesy, T	1
Mikkelsen, T	1
Glantz, M	1
Chamberlain, MC	1
Reardon, DA	2
Wen, PY	2
O'Leary, B	1
Mandeville, HC	1
Fersht, N	1
Solda, F	1
Mycroft, J	1
Zacharoulis, S	1
Vaidya, S	1
Saran, F	1
Nagane, M	1
Nozue, K	1
Shimizu, S	1
Waha, A	1
Miyazaki, H	1
Kurita, H	1
Homori, M	1
Fujioka, Y	1
Shiokawa, Y	1
Armstrong, TS	1
Cao, Y	1
Scheurer, ME	1
Vera-Bolaños, E	1
Manning, R	1
Okcu, MF	1
Bondy, M	1
Zhou, R	1
Gilbert, MR	1
Zwinkels, H	1
Roon, K	1
Jeurissen, FJ	1
Taphoorn, MJ	1
Hop, WC	1
Vecht, CJ	1
Kefford, RF	1
Thomas, NP	1
Corrie, PG	1
Palmer, C	1
Abdi, E	1
Kotasek, D	1
Beith, J	1
Ranson, M	1
Mortimer, P	1
Watson, AJ	2
Margison, GP	2
Middleton, MR	2
Trinh, VA	1
Patel, SP	1
Hwu, WJ	1
Casey, DA	1
Wexler, LH	1
Merchant, MS	1
Chou, AJ	1
Merola, PR	1
Price, AP	1
Meyers, PA	1
Drappatz, J	1
Norden, AD	1
Wong, ET	1
Doherty, LM	1
Lafrankie, DC	1
Ciampa, A	1
Kesari, S	1
Sceppa, C	1
Gerard, M	1
Phan, P	1
Batchelor, TT	1
Ligon, KL	1
Young, G	1
Muzikansky, A	1
Weiss, SE	1
Sure, D	1
Dunn, I	1
Norden, A	1
Anderson, WS	1
Sharp, JR	1
Bouffet, E	1
Stempak, D	1
Gammon, J	1
Stephens, D	1
Johnston, DL	1
Eisenstat, D	1
Hukin, J	1
Samson, Y	1
Bartels, U	1
Tabori, U	1
Huang, A	1
Baruchel, S	1
Preusser, M	1
Elandt, K	1
Schwarzinger, I	1
Marosi, C	1
Heinzl, H	1
Noël, G	1
Schott, R	1
Froelich, S	1
Gaub, MP	1
Boyer, P	1
Fischer-Lokou, D	1
Dufour, P	1
Kehrli, P	1
Maitrot, D	1
Patel, S	1
DiBiase, S	1
Meisenberg, B	1
Flannery, T	1
Patel, A	1
Dhople, A	1
Cheston, S	1
Amin, P	1
Yang, QY	1
Shen, D	1
Sai, K	1
Mu, YG	1
Jiang, XB	1
Zhang, XH	1
Chen, ZP	1
Minniti, G	1
Lanzetta, G	1
Scaringi, C	1
Caporello, P	1
Salvati, M	1
Arcella, A	1
De Sanctis, V	1
Giangaspero, F	1
Enrici, RM	1
Pinnix, CC	1
Fontanilla, HP	1
Hayes-Jordan, A	1
Subbiah, V	1
Bilton, SD	1
Chang, EL	1
Grosshans, DR	1
McAleer, MF	1
Sulman, EP	1
Woo, SY	1
Anderson, P	1
Green, HL	1
Mahajan, A	1
Vredenburgh, JJ	1
Herndon, JE	2
Coan, A	1
Gururangan, S	2
Peters, KB	1
McLendon, R	1
Sathornsumetee, S	1
Rich, JN	2
Lipp, ES	1
Janney, D	1
Friedman, HS	2
Simó, M	1
Velasco, R	1
Graus, F	1
Verger, E	1
Gil, M	1
Pineda, E	1
Blasco, J	1
Bruna, J	1
Lashford, LS	1
Thiesse, P	1
Jouvet, A	1
Jaspan, T	1
Couanet, D	1
Griffiths, PD	1
Doz, F	1
Ironside, J	1
Robson, K	1
Hobson, R	2
Dugan, M	1
Pearson, AD	1
Vassal, G	2
Frappaz, D	1
Agarwala, SS	1
Kirkwood, JM	1
Newlands, ES	2
Foster, T	1
Zaknoen, S	2
Riccardi, A	1
Mazzarella, G	2
Cefalo, G	2
Garrè, ML	2
Massimino, M	2
Sandri, A	2
Ridola, V	2
Ruggiero, A	2
Mastrangelo, S	1
Lazzareschi, I	2
Caldarelli, M	2
Maira, G	1
Madon, E	2
Riccardi, R	2
Strauss, SJ	1
Marples, M	1
Napier, MP	1
Meyer, T	1
Boxall, J	1
Rustin, GJ	2
Rudek, MA	1
Donehower, RC	1
Statkevich, P	1
Batra, VK	2
Cutler, DL	2
Baker, SD	1
Brandes, AA	1
Basso, U	1
Reni, M	1
Vastola, F	1
Tosoni, A	1
Cavallo, G	1
Scopece, L	1
Ferreri, AJ	1
Panucci, MG	1
Monfardini, S	1
Ermani, M	1
Plummer, ER	1
Jones, C	1
Olsen, A	1
Hickson, I	1
McHugh, P	1
McGown, G	1
Thorncroft, M	1
Boddy, AV	1
Calvert, AH	2
Harris, AL	1
Newell, DR	1
Curtin, NJ	1
Koch, D	1
Wick, W	1
Colosimo, C	1
Attinà, G	1
Maurizi, P	1
Di Rocco, C	1
Abate, ME	1
Clerico, A	1
Omuro, AM	1
Raizer, JJ	1
Demopoulos, A	1
Malkin, MG	1
Abrey, LE	1
Gerber, DE	1
Grossman, SA	1
Zeltzman, M	1
Parisi, MA	1
Kleinberg, L	1
Rubie, H	1
Chisholm, J	1
Defachelles, AS	1
Morland, B	1
Munzer, C	1
Valteau-Couanet, D	1
Mosseri, V	1
Bergeron, C	1
Weston, C	1
Coze, C	1
Auvrignon, A	1
Djafari, L	1
Baunin, C	1
Dickinson, F	1
Brisse, H	1
McHugh, K	1
Biassoni, L	1
Giammarile, F	1
Larkin, JM	1
Hughes, SA	1
Beirne, DA	1
Patel, PM	1
Gibbens, IM	1
Bate, SC	1
Thomas, K	1
Eisen, TG	1
Gore, ME	1
Bleehen, NM	1
Lee, SM	1
Thatcher, N	1
Selby, P	1
Brampton, M	1
Stevens, MF	1
Jen, JF	1
Pai, SM	1
Affrime, MB	1
Zambas, DN	1
Heft, S	1
Hajian, G	1
Spiro, TP	1
Liu, L	1
Majka, S	1
Haaga, J	1
Willson, JK	1
Gerson, SL	1
Cokgor, L	1
Edwards, S	1
Affronti, ML	1
Quinn, JA	1
Provenzale, JM	1
McLendon, RE	1
Tourt-Uhlig, S	1
Sampson, JH	1
Stafford-Fox, V	1
Early, M	1
Friedman, AH	1
Bafaloukos, D	1
Gogas, H	1
Georgoulias, V	1
Briassoulis, E	1
Fountzilas, G	1
Samantas, E	1
Kalofonos, Ch	1
Skarlos, D	1
Karabelis, A	1
Kosmidis, P	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients[NCT02227576]	Phase 2	20 participants (Actual)	Interventional	2014-07-10	Terminated (stopped due to Study halted for efficacy following the results of the interim analysis provided for in the protocol on 20 patients.)
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621]	Phase 2	135 participants (Actual)	Interventional	2019-03-25	Completed
Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326]	Phase 2	21 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347]	Phase 1	18 participants (Anticipated)	Interventional	2021-01-01	Recruiting
Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975]	Phase 2	35 participants (Anticipated)	Interventional	2022-05-02	Recruiting
Phase II Trial of Pulse Dosing of Lapatinib in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-Diagnosed Glioblastoma Multiforme[NCT01591577]	Phase 2	50 participants (Actual)	Interventional	2012-12-07	Active, not recruiting
UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036]	Phase 2	50 participants (Anticipated)	Interventional	2021-10-07	Recruiting
A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors[NCT01076530]	Phase 1	27 participants (Actual)	Interventional	2010-02-28	Completed
Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125]	Phase 2	25 participants (Anticipated)	Interventional	2019-02-01	Recruiting
Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097]		82 participants (Actual)	Observational	2014-04-15	Completed
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]	Phase 2	11 participants (Actual)	Interventional	2010-10-14	Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma[NCT05532397]		10 participants (Anticipated)	Interventional	2023-02-17	Recruiting
Phase II Study of Temozolomide (Temodal) in Children Over 1 Year of Age With Relapsed or Refractory High Risk Neuroblastoma[NCT00276679]	Phase 2	0 participants	Interventional	2003-04-30	Completed
Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075]	Phase 2	25 participants (Actual)	Interventional	2002-07-31	Completed
A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595]	Phase 2	0 participants (Actual)	Interventional	2009-02-28	Withdrawn (stopped due to No patients accrued since study opened)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

One-year Progression-free Survival and Overall Survival

Intervention	dose in mg/m^2 (Number)
DRBEAT Regimen	773.25

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

Overall Survival

Percentage of Participants With Distant Brain Failure (DBF) at One Year

Intervention	Days (Median)
	Progression Free Survival	Overall Survival
DRBEAT Regimen	132	564

Intervention	weeks (Median)
Radiosurgery 15-24 Gy + Adjuvant Temozolomide	31

Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years

temozolomide and Thrombopenia